CRL-2868 Search Results


hcc827 human nsclc tumor cells  (ATCC)
99
ATCC hcc827 human nsclc tumor cells
Figure 4. Biological activity of CD137 antibody 7A5 in human tumor xenograft mouse models reconstituted with human immune cells in vivo. A, Dose-dependent antitumor efficacy of 7A5 in <t>HCC827</t> established tumors in NSG mice infused on day 31 (dashed arrow) with human expanded T cells (n ¼ 11 per group). Control human IgG1 (10 mg/kg), 7A5 (10 and 1 mg/kg), and anti–PD-L1 antibody (10 mg/kg) were dosed once weekly as indicated by arrows. B, Antitumor efficacy study in HCC827 established tumors in NSG mice infused on day 32 (dashed arrow) with human expanded T cells (n ¼ 7–8 per group). Control human IgG1 (10 mg/kg), 7A5 (10 mg/kg), anti–PD-L1 antibody (1 mg/kg), and the combination of both 7A5 and anti–PD-L1 (10 and 1 mg/kg accordingly) was dosed once weekly as indicated by arrows. C, Antitumor efficacy study in NSG mice coimplanted with NCI-H292 tumor cells and human PBMCs. Treatment with control human IgG1, 7A5, anti–PD-L1 antibody, and the combination of both 7A5 and anti–PD-L1 was given once weekly at indicated doses as shown by arrows (7A5 dashed arrow, anti–PD-L1 solid arrow; n ¼ 8 per group). The geometric tumor volumes are presented as mean SEM (A–C).
Hcc827 Human Nsclc Tumor Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/hcc827 human nsclc tumor cells/product/ATCC
Average 99 stars, based on 1 article reviews
hcc827 human nsclc tumor cells - by Bioz Stars, 2026-02
99/100 stars
  Buy from Supplier
gene encoding ompaper  (ATCC)
90
ATCC gene encoding ompaper
Figure 4. Biological activity of CD137 antibody 7A5 in human tumor xenograft mouse models reconstituted with human immune cells in vivo. A, Dose-dependent antitumor efficacy of 7A5 in <t>HCC827</t> established tumors in NSG mice infused on day 31 (dashed arrow) with human expanded T cells (n ¼ 11 per group). Control human IgG1 (10 mg/kg), 7A5 (10 and 1 mg/kg), and anti–PD-L1 antibody (10 mg/kg) were dosed once weekly as indicated by arrows. B, Antitumor efficacy study in HCC827 established tumors in NSG mice infused on day 32 (dashed arrow) with human expanded T cells (n ¼ 7–8 per group). Control human IgG1 (10 mg/kg), 7A5 (10 mg/kg), anti–PD-L1 antibody (1 mg/kg), and the combination of both 7A5 and anti–PD-L1 (10 and 1 mg/kg accordingly) was dosed once weekly as indicated by arrows. C, Antitumor efficacy study in NSG mice coimplanted with NCI-H292 tumor cells and human PBMCs. Treatment with control human IgG1, 7A5, anti–PD-L1 antibody, and the combination of both 7A5 and anti–PD-L1 was given once weekly at indicated doses as shown by arrows (7A5 dashed arrow, anti–PD-L1 solid arrow; n ¼ 8 per group). The geometric tumor volumes are presented as mean SEM (A–C).
Gene Encoding Ompaper, supplied by ATCC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/gene encoding ompaper/product/ATCC
Average 90 stars, based on 1 article reviews
gene encoding ompaper - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
hcc827-gas-luc2  (ATCC)
93
ATCC hcc827-gas-luc2
Figure 4. Biological activity of CD137 antibody 7A5 in human tumor xenograft mouse models reconstituted with human immune cells in vivo. A, Dose-dependent antitumor efficacy of 7A5 in <t>HCC827</t> established tumors in NSG mice infused on day 31 (dashed arrow) with human expanded T cells (n ¼ 11 per group). Control human IgG1 (10 mg/kg), 7A5 (10 and 1 mg/kg), and anti–PD-L1 antibody (10 mg/kg) were dosed once weekly as indicated by arrows. B, Antitumor efficacy study in HCC827 established tumors in NSG mice infused on day 32 (dashed arrow) with human expanded T cells (n ¼ 7–8 per group). Control human IgG1 (10 mg/kg), 7A5 (10 mg/kg), anti–PD-L1 antibody (1 mg/kg), and the combination of both 7A5 and anti–PD-L1 (10 and 1 mg/kg accordingly) was dosed once weekly as indicated by arrows. C, Antitumor efficacy study in NSG mice coimplanted with NCI-H292 tumor cells and human PBMCs. Treatment with control human IgG1, 7A5, anti–PD-L1 antibody, and the combination of both 7A5 and anti–PD-L1 was given once weekly at indicated doses as shown by arrows (7A5 dashed arrow, anti–PD-L1 solid arrow; n ¼ 8 per group). The geometric tumor volumes are presented as mean SEM (A–C).
Hcc827 Gas Luc2, supplied by ATCC, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/hcc827-gas-luc2/product/ATCC
Average 93 stars, based on 1 article reviews
hcc827-gas-luc2 - by Bioz Stars, 2026-02
93/100 stars
  Buy from Supplier

Image Search Results


Figure 4. Biological activity of CD137 antibody 7A5 in human tumor xenograft mouse models reconstituted with human immune cells in vivo. A, Dose-dependent antitumor efficacy of 7A5 in HCC827 established tumors in NSG mice infused on day 31 (dashed arrow) with human expanded T cells (n ¼ 11 per group). Control human IgG1 (10 mg/kg), 7A5 (10 and 1 mg/kg), and anti–PD-L1 antibody (10 mg/kg) were dosed once weekly as indicated by arrows. B, Antitumor efficacy study in HCC827 established tumors in NSG mice infused on day 32 (dashed arrow) with human expanded T cells (n ¼ 7–8 per group). Control human IgG1 (10 mg/kg), 7A5 (10 mg/kg), anti–PD-L1 antibody (1 mg/kg), and the combination of both 7A5 and anti–PD-L1 (10 and 1 mg/kg accordingly) was dosed once weekly as indicated by arrows. C, Antitumor efficacy study in NSG mice coimplanted with NCI-H292 tumor cells and human PBMCs. Treatment with control human IgG1, 7A5, anti–PD-L1 antibody, and the combination of both 7A5 and anti–PD-L1 was given once weekly at indicated doses as shown by arrows (7A5 dashed arrow, anti–PD-L1 solid arrow; n ¼ 8 per group). The geometric tumor volumes are presented as mean SEM (A–C).

Journal: Molecular Cancer Therapeutics

Article Title: Characterization of 7A5: A Human CD137 (4-1BB) Receptor Binding Monoclonal Antibody with Differential Agonist Properties That Promotes Antitumor Immunity

doi: 10.1158/1535-7163.mct-19-0893

Figure Lengend Snippet: Figure 4. Biological activity of CD137 antibody 7A5 in human tumor xenograft mouse models reconstituted with human immune cells in vivo. A, Dose-dependent antitumor efficacy of 7A5 in HCC827 established tumors in NSG mice infused on day 31 (dashed arrow) with human expanded T cells (n ¼ 11 per group). Control human IgG1 (10 mg/kg), 7A5 (10 and 1 mg/kg), and anti–PD-L1 antibody (10 mg/kg) were dosed once weekly as indicated by arrows. B, Antitumor efficacy study in HCC827 established tumors in NSG mice infused on day 32 (dashed arrow) with human expanded T cells (n ¼ 7–8 per group). Control human IgG1 (10 mg/kg), 7A5 (10 mg/kg), anti–PD-L1 antibody (1 mg/kg), and the combination of both 7A5 and anti–PD-L1 (10 and 1 mg/kg accordingly) was dosed once weekly as indicated by arrows. C, Antitumor efficacy study in NSG mice coimplanted with NCI-H292 tumor cells and human PBMCs. Treatment with control human IgG1, 7A5, anti–PD-L1 antibody, and the combination of both 7A5 and anti–PD-L1 was given once weekly at indicated doses as shown by arrows (7A5 dashed arrow, anti–PD-L1 solid arrow; n ¼ 8 per group). The geometric tumor volumes are presented as mean SEM (A–C).

Article Snippet: HCC827 human NSCLC tumor cells (ATCC) were injected subcutaneously into the right flank of female NSG mice (10 106 cells).

Techniques: Activity Assay, In Vivo, Control